Australia is making it harder to protect inventions, says PhRMA

25 April 2017
medical_legal_law_big

Bringing a single new medicine to market requires substantial resources over many years. To ensure continued investment in the development of tomorrow’s breakthrough treatments and cures, innovators must be able to protect and enforce patents and other intellectual property, says Jay Taylor of Pharmaceutical and Research Manufacturers of America (PhRMA).

Patents provide temporary protection for new inventions, but it’s up to innovators to enforce those protections. When enforcement is necessary, it’s critical that patent-holders are able to ask the court for a temporary injunction—an important safeguard that prohibits potentially infringing products from entering the market until the dispute has been resolved.

Unfortunately, Australia is discouraging inventors from seeking injunctions to stop products that may violate a patent from entering the market. They are making it harder for American biopharmaceutical innovators to fight patent infringement. Specifically, the Australian government is seeking “market-size damages” from inventors that unsuccessfully seek to enforce their patents in court. If a court rules a patent is invalid or not infringed, the inventor must not only compensate its rival for lost sales, but also pay the government the difference in price between a patented medicine and its generic counterpart during the period of a preliminary injunction. The government’s share can amount to a significant financial penalty, which could cost an inventor even more than the total expected return of the patented medicine.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical